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Abstract: In the recent of years, the use of lipid nanoparticles (LNPs) for RNA delivery has gained
considerable attention, with a large number in the clinical pipeline as vaccine candidates or to
treat a wide range of diseases. Microfluidics offers considerable advantages for their manufacture
due to its scalability, reproducibility and fast preparation. Thus, in this study, we have evaluated
operating and formulation parameters to be considered when developing LNPs. Among them,
the flow rate ratio (FRR) and the total flow rate (TFR) have been shown to significantly influence
the physicochemical characteristics of the produced particles. In particular, increasing the TFR or
increasing the FRR decreased the particle size. The amino lipid choice (cationic—DOTAP and DDAB;
ionisable—MC3), buffer choice (citrate buffer pH 6 or TRIS pH 7.4) and type of nucleic acid payload
(PolyA, ssDNA or mRNA) have also been shown to have an impact on the characteristics of
these LNPs. LNPs were shown to have a high (>90%) loading in all cases and were below 100 nm
with a low polydispersity index (≤0.25). The results within this paper could be used as a guide for
the development and scalable manufacture of LNP systems using microfluidics.
Keywords: microfluidics; RNA; lipid nanoparticles; manufacture; critical process parameters;
nucleic acid
1. Introduction
RNA therapeutics is a promising approach to treat a wide range of medical conditions including cancer
and infectious diseases [1]. However, these molecules are rapidly cleared or degraded upon administration,
showing limited systemic potency in vivo [2]. In addition, their size and negative charge impede
crossing the cell membrane [3]. Thus, specialised delivery systems are required for the efficient
intracellular RNA delivery to the target site. Development of clinical therapeutic RNA is currently
riding on a high, since the recent approvals of the first two siRNA drugs: patisiran (2018) and
givosiran (2019) [4,5]. Patisiran is a lipid nanoparticle (LNP)-formulated siRNA used for the
treatment of hereditary transthyretin-mediated amyloidosis. In contrast, givosiran is based on
siRNA conjugated with a targeting moiety, which consists of three N-acetylgalactosamine (GalNAc)
molecules. In addition to this, currently, a large number of vaccines are being developed against severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using LNP technology for mRNA delivery
(e.g., Moderna, CureVac, BioNTech) [1]. Nucleic acid-loaded LNP systems are complex structures
(approximately 100 nm), typically composed of amino lipids (ionisable or cationic amino lipids) as the
main component, phosphatidylcholine lipids, cholesterol and a polyethylene glycol-lipid conjugate
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(PEG-lipid). The development of ionisable cationic lipids has been a major breakthrough in the LNP field.
These lipids are positively charged at an acidic pH and become neutrally charged at a physiological
pH [6]. This quality grants them the advantage of electrostatically interacting with the negatively
charged nucleic acid at a lower pH and allows the LNPs to deliver the cargo within the cytosol via an
ApoE-mediated pathway, increasing LNP potency compared to the permanently charged cationic lipids.
As a result, ionisable LNPs are not rapidly cleared by the reticuloendothelial system. Upon reaching the
target cell, they become engulfed via endocytosis and become positively charged within the endosome
(internal pH 5–6), fusing with the naturally occurring negatively charged endosomal lipids and
therefore releasing the nucleic acid into the cytosol. For an optimal efficacy in the liver after intravenous
administration, it has been demonstrated that ionisable lipids should have a pKa between 6.2 and 6.5 [7].
An example of this is the ionisable lipid Dlin-MC3-DMA, which has a pKa of 6.44 and is used within the
approved patisiran formulation (Onpattro®, Alnylam Pharmaceuticals, Cambridge, MA, USA) [7,8].
PEG-lipids are also incorporated into the formulations to facilitate the production of nanometre-sized
particles and to increase both particle stability, due to the steric interactions, and in vivo half-life.
However, PEG-lipids may impair cellular uptake and therefore the use of “diffusible” PEG-lipids
(which rapidly separate from the LNPs) is recommended for hepatic delivery. Thus, these lipid
components have been shown to be critical and need to be at specific proportions within the LNP
system [9].
Traditional methods for LNP manufacture have previously involved the production of a lipid
film and subsequent hydration of the film with an aqueous buffer containing the nucleic acid to
passively encapsulate the payload [10]. This commonly results in large (>100 nm) and heterogeneous
particles with a low encapsulation yield, requiring the addition of a down-sizing technique such as
extrusion or sonication. In addition to this, this method is difficult to scale-up and lacks reproducibility.
Thus, the development of ethanol injection and microfluidic techniques during the early 2000s
revolutionised LNP manufacturing [11,12]. Microfluidics is robust, scalable and very reproducible.
It involves the mixture of lipids in an organic solvent with an aqueous phase containing the nucleic
acid through a micromixer. The cationic lipid interacts with the negatively charged nucleic acid,
resulting in high encapsulation efficiencies. LNPs of defined sizes can be accurately produced by
controlling the microfluidic operating parameters such as flow rate ratio (FRR) or total flow rate (TFR).
High production speeds (TFR) can be achieved using microfluidics, which results in a reduction in
manufacturing time (up to 200 mL/min).
Here, we assessed the effects of formulation and microfluidic operating parameters during the
production of LNPs, to provide practical information towards their development and manufacture.
We evaluated the effects of the TFR and the FRR on LNP formulations containing either cationic
(DOTAP-cLNPs or DDAB-cLNPs) or ionisable (MC3-iLNPs or GenVoy-ILMTM-iLNPs) lipids,
which had previously been shown to be effective as LNP vaccine formulations [13]. In addition,
formulation parameters such as lipid molar ratio composition, structural lipid, coating lipid and
buffer choices were also evaluated. After formulation optimisation, PolyA, ssDNA and mRNA were
encapsulated within the cLNPs and iLNPs, demonstrating the ability of microfluidic technology to
accommodate a wide range of nucleic acids for LNP preparation.
2. Materials and Methods
2.1. Materials
Fully hydrogenated soy phosphatidylcholine (HSPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)
and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000] (DSPE-PEG2000)
were obtained from Lipoid (Ludwigshafen, Germany). 1,2-dioleoyl-3-trimethylammoniumpropane
(chloride salt) (DOTAP), dimethyldioctadecylammonium (Bromide Salt) (DDAB) and 1,2-dimyristoyl-
rac-glycero-3-methoxypolyethylene glycol-2000 (DMG-PEG2000) were purchased from Avanti Polar
Lipids (Alabaster, AL, USA). Cholesterol (Chol), citric acid, sodium citrate tribasic dehydrate,
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polyadenylic acid (PolyA) and single stranded deoxyribonucleic acid (ssDNA) from salmon
testes were acquired from Sigma-Aldrich (St. Louis, MO, USA). Phosphate-buffered saline
tablets (PBS pH 7.4) were acquired from Oxoid Ltd. (Basingstoke, UK). Tris (hydroxymethyl)
aminomethane (TRIS-base) and ethanol (EtOH) were obtained from Fisher Scientific, Loughborough,
UK. The ionisable lipid heptatriaconta-6, 9, 28, 31-tetraen-19-yl 4-(dimethylamino) butanoate
(Dlin-MC3-DMA or MC3) was purchased from Biorbyt Limited (Cambridge, UK). GenVoy-ILMTM is
a commercially available proprietary lipid mix composition comprising DSPC:cholesterol:ionisable
lipid:stabilizer at 10:37.5:50:2.5 mol% for encapsulating nucleic acids, manufactured by Precision
NanoSystems Inc. Messenger RNA (CleanCap® mRNA Fluc, L-7602) from TriLink BioTechnologies
(San Diego, CA, USA) was gifted by Precision NanoSystems Inc. (Vancouver, BC, Canada). All solvents
and other chemicals were of analytical grade, and milliQ-water was provided by an in-house system.
2.2. Microfluidics
Lipid nanoparticles (LNPs) were prepared using the NanoAssemblr® Benchtop from Precision
NanoSystems Inc. (Vancouver, BC, Canada) which uses a Y-shape staggered herringbone
micromixer [14]. Cationic lipid nanoparticles (cLNPs) were composed of DSPC:Chol:DOTAP:DMG-
PEG2000 or DSPC:Chol:DDAB:DMG-PEG2000, whereas ionisable lipid nanoparticles (iLNPs) were
composed of DSPC:Chol:MC3:DMG-PEG2000. Individual lipid stocks were prepared in ethanol.
Unless otherwise stated, lipid mixtures were dissolved in ethanol at 10:48:40:2 molar ratio
for Structural:Chol:cationic/ionisable:PEG-lipid respectively (based on research carried out by
Geall et al. [15]). The final lipid concentration after microfluidic production was 2 mg/mL in all
cases. Citrate buffer pH 6 100 mM was used as aqueous phase. The effect of the production speed
(TFR; 5–20 mL/min) and the aqueous-to-organic ratio (FRR; 1:1 to 5:1) was evaluated. Effect of the
condensing lipid (DDAB, DOTAP or MC3), coating lipid (DMG-PEG2000 vs. DSPE-PEG2000) and
structural lipid choice (HSPC vs. DSPC) was assessed. Besides, the effect of the lipid molar ratio and
the choice of aqueous buffer (citrate buffer pH 6 100 mM vs. TRIS buffer pH 7.4 10 mM) was studied.
For the preparation of cLNPs or iLNPs encapsulating either PolyA, ssDNA or mRNA, these were added
into the aqueous phase (citrate buffer pH 6, 100 mM) at the nitrogen-to-phosphate ratio (N/P; nitrogen
from the cationic/ionisable lipid and phosphate from the nucleic acid) of 8. Initial and final waste
volumes were set at 0.25 and 0.05 mL respectively. To facilitate the explanation of the experiments
we will refer to the LNPs produced with DOTAP or DDAB as cationic lipid nanoparticles (cLNPs)
and the LNPs containing the ionisable lipid MC3 as ionisable lipid nanoparticles (iLNPs) (Figure 1).
Formulations were dialysed (MWCO 12,000–14,000 Da, Sigma-Aldrich, St. Louis, MO, USA) for 1 h
under magnetic stirring against 200 mL PBS or TRIS buffer for iLNPs (MC3) and cLNPs (DDAB or
DOTAP) respectively. This process is sufficient to reduce residual solvent levels to below 5000 ppm
(results not shown). Whilst generally PBS is the default choice of buffer, TRIS buffer was adopted
for cLNPs, as cationic lipid-based systems are sensitive to high salt buffers such as PBS and are known
to precipitate.
2.3. Scalable Production of Lipid Nanoparticles Using a Toroidal Micromixer (TrM)
GenVoy-ILM™, a proprietary ionisable lipid mix formulation loaded with PolyA (N/P 6), was produced
using different microfluidic mixers: a staggered herringbone (SHM) and a toroidal mixer (TrM)
(NanoAssemblr Classic and NxGen™ respectively; Precision NanoSystems Inc., Vancouver, BC, Canada).
GMP microfluidic production of LNPs was achieved using the NanoAssemblr GMP system and a
TrM (NxGen 500) cartridge (Precision NanoSystems Inc. (Vancouver, BC, Canada), which uses the
same toroidal mixer design with inline dilution and with custom HPLC pumps. Production speeds
from 12 mL/min up to 200 mL/min were tested. The produced GenVoy-ILM™-based Poly (A) iLNP
nanoparticles were diluted to an ethanol concentration below 1%. An aliquot of the GenVoy-ILM™ iLNP
formulations were further ultra-centrifuged at 3000 RPM using 10 kDa MWCO Amicon Ultrafiltration
units (Sigma-Aldrich, St. Louis, MO, USA) for the removal of solvent.
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on the ionisable lipid DLin-MC3-DMA. All described formulations contain DSPC and cholesterol as 
structural lipids and DMG-PEG2000 as the coating lipid. Unless otherwise stated, the lipid molar ratio 
used was 10:48:40:2 for DSPC:cholesterol:cationic/ionisable:PEG-lipid. The molecular structures of 
each component are shown in the figure along with the schematic representation of the structure of a 
lipid nanoparticle loaded with nucleic acids. 
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measured by dynamic light scattering (DLS) using a Zetasizer Nano ZS (Malvern Panalytical Ltd., 
Worcestershire, UK) equipped with a 633 nm laser and a detection angle of 173°. LNPs were diluted 
in filtered (0.22 µm) ultrapure water down to 0.2 mg/mL LNP concentration. 1000 µL of diluted 
particles were added into a 4-mL cuvette. The same dilution was used for zeta potential 
measurements. The dispersant (water) refractive index (RI) and viscosity values were 1.330 and 
0.8872 cP respectively, whereas the material absorbance and RI were 0.01 and 1.49 respectively. 
Zetasizer Software v.7.11 (Malvern Panalytical Ltd., Worcestershire, UK) was used for the acquisition 
of data. All measurements were undertaken in triplicate with the attenuation value between 7 and 8. 
2.5. TNS Fluorescence Titration Assay 
The surface pKa of the ionisable lipid contained in the GenVoy-ILM™ formulation was studied 
alongside DSPC:Chol:DOTAP:DMG-PEG2000 cLNPs (10:38.5:50:1.5 mol%). Amino lipid pKa values 
were determined for each LNP system by measuring the fluorescence of 2-(p-toluidino)-6-napthalene 
sulfonic acid (TNS) during titration with buffer solutions with pH from 3.5 to 9 with 0.5 pH unit 
increments (10 mM HEPES, 130 mM NaCl, 10 mM NH4Oac, 10 mM MES). Formulation were diluted 
Figure 1. Lipid nanoparticles selected for optimisation. Cationic lipid nanoparticles (cLNPs) are based
on either the cationic lipid DOTAP or DAB, whereas ionisable lipid nanoparticles (iLNPs) are based
on the ionisable lipid DLin-MC3-DMA. All described formulations contain DSPC and cholesterol as
structural lipids and DMG-PEG2000 as the coating lipid. Unless otherwise stated, the lipid molar ratio
used was 10:48:40:2 for DSPC:cholesterol:cationic/ionisable:PEG-lipid. The molecular structures of each
component are shown in the figure along with the schematic representation of the structure of a lipid
nanoparticle loaded with nucleic acids.
2.4. LNP Characterisation: Particle Size, Polydispersity and Zeta Potential
Particle size (Z-average diameter), polydispersity index (PDI) and zeta potential (ZP) were
measured by dynamic light scattering (DLS) using a Zetasizer Nano ZS (Malvern Panalytical Ltd.,
Worcestershire, UK) equipped with a 633 nm laser and a detection angle of 173◦. LNPs were diluted
in filtered (0.22 µm) ultrapure water down to 0.2 mg/mL LNP concentration. 1000 µL of diluted
particles were added into a 4-mL cuvette. The same dilution was used for zeta potential measurements.
The dispersant (water) refractive index (RI) and viscosity values were 1.330 and 0.8872 cP respectively,
whereas the material absorbance and RI were 0.01 and 1.49 respectively. Zetasizer Software v.7.11
(Malvern Panalytical Ltd., Worcestershire, UK) was used for the acquisition of data. All measurements
were undertaken in triplicate with the attenuation value between 7 and 8.
2.5. TNS Fluorescence Titration Assay
The surface pKa of the ionisable lipid contained in the GenVoy-ILM™ formulation was studied
alongside DSPC:Chol:DOTAP:DMG-PEG2000 cLNPs (10:38.5:50:1.5 mol%). Amino lipid pKa values
were determined for each LNP system by measuring the fluorescence of 2-(p-toluidino)-6-napthalene
sulfonic acid (TNS) during titration with buffer solutions with pH from 3.5 to 9 with 0.5 pH unit
increments (10 mM HEPES, 130 mM NaCl, 10 mM NH4Oac, 10 mM MES). Formulation were diluted
to 0.78 mM with milliQ-water and 6.4 µL was added to a black 96-well plate with 233.6 µL of pH
buffer and 10 µL of 25 µM TNS solution. Fluorescence was quantified at λem = 445 nm, λex = 321 nm.
Sigmoidal best-fit analyses were applied to the titration curves, and pKa, defined as pH at half-maximal
fluorescence intensity, was observed.
2.6. Quantific tion of Nucleic Acid Loading: Poly(A), ssDNA and mRNA
Nucleic acid (PolyA, ssDNA and mRNA) encapsulation efficiency (EE%) was measured using
Quant-iT™ RiboGreen™ RNA Assay Kit (Invitrogen™, Thermo Fisher Scientific, Waltham, MA, USA).
Briefly, 100 µL of the diluted fluorescent dye was a ded to 100 µL of diluted liposomes in the presence
or absence of 1% (w/v) riton-X and incubated in absence of light for 5 min. Nucleic acids were
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quantified by measuring fluorescence (λem = 520 nm, λex = 480 nm) using a fluorimeter (Polarstar
Omega, BMG Labtech). A linear calibration curve up to 1500 ng/mL was obtained (R2 ≥ 0.998) for each
of the nucleic acid tested. Calculated limit of detection (LOD) and limit of quantification (LOQ) were
73 and 221 ng/mL, 61 and 184 ng/mL and 90 and 272 ng/mL for PolyA, ssDNA and mRNA respectively
and all analyses were performed between LOQ and 1500 ng/mL.
2.7. Cryogenic Transmission Electron Microscopy (Cryo-TEM)
Cryo-TEM images of the blank and mRNA-cLNPs for microscopy were prepared by placing 5 µL
of LNPs onto a 400-mesh lacey carbon-coated grid using single-sided blotting for 2 s, then immediately
immersing the sample grid into nitrogen-cooled ethane (100% ethane). LNP morphology was then
observed using the Jeol Jem F-200 microscope (Joel, Tokyo, Japan) at liquid nitrogen temperature and
200 kV.
Cryo-TEM images of the blank and GenVoy-ILM™ encapsulated mRNA iLNPs were performed
as per Belliveau et al. [16] with slight modifications. The mRNA LNPs used for CryoTEM imaging
were downstream processed and concentrated to the desired RNA concentration using 10 kDa MWCO
Amicon Ultra filter units. Briefly, LNPs were approximately concentrated to more than the target
RNA concentration using Amicon Ultra Filtration. The concentration was assessed by the modified
Quant-iT™ RiboGreen™ RNA Assay and adjusted using 0.1 × PBS. Alternatively, if the concentration
was found to be below the target concentration, the ultrafiltration using Amicon Ultra filters was
continued until the final target concentration is achieved. The concentrated samples were then
prepared by applying 3 µL of LNPs to a glow discharged Lacey Carbon 300 mesh copper TEM grid.
Excess liquid was removed by blotting with a Vitrobot™Mark VI robots (Thermo Fisher Scientific,
Waltham, MA, USA) and then plunge-freezing the sample in liquid ethane to rapidly freeze the vesicles
in a thin film of amorphous ice. Samples were cryogenically imaged using a 300 kV FEI Titan Krios
TEM with a high-resolution Falcon III Electron detector.
2.8. Statistical Analysis
Results are represented as mean ± SD of at least n = 3 independent batches. ANOVA tests were
used to assess statistical significance, with a Tukey’s post ad-hoc test (p-value of less than 0.05).
3. Results
3.1. Method Optimisation for Lipid Nanoparticles (LNPs)
3.1.1. Effect of Microfluidic Operating Parameters: Total Flow Rate and Flow Rate Ratio
Initially, cationic lipid nanoparticles (cLNPs) and ionisable lipid nanoparticles (iLNPs) were
produced by mixing lipids in ethanol with citrate buffer (pH 6 100 mM) using a staggered
herringbone micromixer, followed by dialysis in TRIS buffer (for cLNPs) or PBS (for iLNPs) at
pH 7.3–7.4 to remove the organic solvent and raise the pH to physiological conditions. All three
LNP systems contained four lipid components namely DSPC, cholesterol, DMG-PEG2000 and a
cationic lipid (either DDAB, DOTAP or MC3) at 10:40:48:2 molar percentage and 2 mg/mL final lipid
concentration after microfluidics production. Important parameters to optimise using microfluidics
are the TFR and the FRR. We started by evaluating the effect of the TFR at a fixed FRR (3:1). Figure 2
shows the particle size, PDI and zeta potential of DDAB and DOTAP cLNPs and MC3 iLNPs
produced at varying speeds (from 5 to 20 mL/min) before (Figure 2a) and after purification via dialysis
(Figure 2b). In general, particle size decreased with increasing TFR from 5 to 10–20 mL/min. The size
of the LNPs stabilised at TFR 10–20 mL/min, with no significant differences observed across these
production speeds. DOTAP-cLNPs showed the smallest particle size at all TFRs tested, followed
by iLNPs and DDAB-cLNPs. The size of DOTAP-cLNPs ranged from 60 to 45 nm, MC3-iLNPs
from 68 to 50 nm and DDAB-cLNPs from 88 to 75 nm for 5 to 20 mL/min, respectively (Figure 2).
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All LNPs were homogeneous in nature (PDI ≤ 0.2), with DDAB-cLNPs showing the most homogeneous
particle sizes (PDI ≤ 0.1) (Figure 2). Purification of the LNPs by dialysis did not impact upon their
particle size. Zeta potential values were neutral for all formulations across the speeds tested (Figure 2).
Regardless of the choice of cationic lipid, the effect of this microfluidic parameter was very similar,
with low production speed forming larger particles and higher speeds decreasing the particle size.
Pharmaceutics 2020, 12, x FOR PEER REVIEW 6 of 19 
 
concentration after microfluidics production. Important parameters to optimise using microfluidics 
are the TFR and the FRR. We started by evaluating the effect of the TFR at a fixed FRR (3:1). Figure 2 
shows the particle size, PDI and zeta potential of DDAB and DOTAP cLNPs and MC3 iLNPs 
produced at varying speeds (from 5 to 20 mL/min) before (Figure 2a) and after purification via 
dialysis (Figure 2b). In general, particle size decreased with increasing TFR from 5 to 10–20 mL/min. 
The size of the LNPs stabilised at TFR 10–20 mL/min, with no significant differences observed across 
these production speeds. DOTAP-cLNPs showed the smallest particle size at all TFRs tested, 
followed by iLNPs and DDAB-cLNPs. The size of DOTAP-cLNPs ranged from 60 to 45 nm, MC3-
iLNPs from 68 to 50 nm and DDAB-cLNPs from 88 to 75 nm for 5 to 20 mL/min, respectively (Figure 
2). All LNPs were homogeneous in nature (PDI ≤ 0.2), with DDAB-cLNPs showing the most 
homogeneous particle size  (PDI ≤ 0.1) (Figure 2). Purification of the LNPs by dialysis did not impact 
upon their particle size. Zeta potential values were neutral for all formulati ns across the speeds 
tested (Figure 2). Regardless of the choice of cationic lipid, he effect of this microfluidic parameter 
was very similar, with l w pr duct on spe d forming larger particles and high  speeds decreasing 
the particle size. 
 
Figure 2. Effect of the total flow rate (TFR) on the physicochemical attributes of DOTAP (pink), MC3 
(blue) and DDAB-based (yellow) lipid nanoparticles produced by microfluidics at 3:1 FRR using 
citrate buffer pH 6 100 mM as an aqueous buffer. cLNPs were purified via dialysis using TRIS buffer 
pH 7.4 10 mM whereas iLNPs were dialysed against PBS pH 7.3 10 mM. Particle size (bars) and PDI 
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dialysis. Results represent the mean of at least 3 independent batches and the standard deviation is 
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no statistical significance observed. 
After evaluation of the TFR, the next step was to assess the effect of the ratio between the aqueous 
(citrate buffer pH 6, 100 mM) and the organic (lipids in ethanol) phases (FRR, Figure 3). In order to 
accelerate the production of these LNP systems, the highest flow rate (20 mL/min) was selected for 
further experimentation. We varied the FRR from 1:1 to 5:1, and all LNP formulations showed a 
similar trend. As the FRR was increased, particle size decreased (Figure 3). LNPs produced at 1:1 FRR 
resulted in the largest particle sizes. DOTAP-cLNPs had a hydrodynamic size of 500 nm and a high 
Figure 2. Effect of the total flow rate (TFR) on the physicochemical attributes of DOTAP (pink),
MC3 (blue) and DDAB-based (yellow) lipid nanoparticles produced by microfluidics at 3:1 FRR using
citrate buffer pH 6 100 mM as an aqueous buffer. cLNPs were purified via dialysis using TRIS buffer
pH 7.4 10 mM whereas iLNPs were dialysed against PBS pH 7.3 10 mM. Particle size (bars) and PDI
(open circles) of the LNPs produced using microfluidics before (a) and after (b) purification via dialysis.
Results represent the mean of at least 3 independent batches and the standard deviation is plotted
as error bars. ZP (zeta potential). Significant differences are shown as * p < 0.05and ‘ns’, when no
statistical significance observed.
After evaluation of the TFR, the next step was to assess the effect of the ratio between the aqueous
(citrate buffer pH 6, 100 mM) and the organic (lipids in ethanol) phases (FRR, Figure 3). In order
to accelerate the production of these LNP systems, the highest flow rate (20 mL/min) was selected
for further experimentation. We varied the FRR from 1:1 to 5:1, and all LNP formulations showed
a similar trend. As the FRR was increased, particle size decreased (Figure 3). LNPs produced at
1:1 FRR resulted in the largest particle sizes. DOTAP-cLNPs had a hydrodynamic size of 500 nm
and a high heterodispersity (PDI > 0.8). DDAB-cLNPs were approximately 800 nm in size with
a PDI of 0.2, while MC3-iLNPs were 200 nm in size, showing PDI values below 0.2 (Figure 3a).
However, the physicochemical characteristics of the LNPs produced at 1:1 FRR changed after dialysis
(Figure 3b). In the case of cLNPs, both DOTAP and DDAB formulations decreased in particle size
down to 180 and 480 nm respectively, while MC3-iLNPs significantly (p < 0.05) increased in size
(up to approximately 700 nm) (Figure 3). In the case of the PDI of the formulations before and after
purification, DOTAP significantly (p < 0.05) decreased to 0.1, MC3 increased to 0.6 while DDAB PDI
remained unchanged. When comparing 3:1 and 5:1 FRR, cLNPs significantly (p < 0.05) decreased in
size from 46 to 37 nm and from 75 to 65 nm for DOTAP and DDAB-cLNPs respectively. MC3-iLNPs
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resulted in sizes of approximately 50 nm at both FRR. All three LNPs showed homogeneous size
distributions (PDI ≤ 0.25), with DDAB-cLNPs showing significantly (p < 0.05) higher homogeneity
(PDI ≤ 0.1) (Figure 3). The zeta potential remained comparable across all three FRR tested.
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3.1.2. Effect of the Lipid Molar Ratio 
Next, we sought how the composition (i.e., lipid molar ratio) affected the particle size, PDI and 
surface charge of these LNP formulations (Figures 4–6). The PEG-lipid and structural lipid DSPC 
were fixed at 2 and 10 mol% respectively. However, the ratio between cholesterol and the cationic 
lipid was varied. The operating microfluidic parameters applied for the assessment of the lipid molar 
ratio effect were 3:1 FRR and 20 mL/min TFR (based upon the previous results). Figure 4 shows the 
effect of the variation of both cholesterol and cationic lipid molar ratio for the DOTAP formulation. 
At low cholesterol content (10 mol%), DOTAP-cLNPs displayed particle sizes of 65 nm and a high 
PDI (≥0.4), which further increased after purification (PDI ≥ 0.7) (Figure 4a,b). Increasing cholesterol 
molar ratio, and consequently decreasing the ratio of cationic lipid, resulted in a decrease in particle 
Figure 3. Effect of the flow rate ratio (FRR) on the production of lipid nanoparticles based either on
DOTAP (pink), MC3 (blue) or DDAB (yellow) at 20 mL/min TFR using citrate buffer pH 6 100 mM as
production buffer. cLNPs were purified via dialysis using TRIS buffer pH 7.4 10 mM whereas iLNPs
were dialysed against PBS pH 7.3 10 mM. Particle size (bars) and PDI (open circles) of the LNPs produced
using microfluidics (a) before and (b) after purification via dialysis. Results represent the mean of at
least 3 independent batches and the standard deviation is plotted as error bars. ZP (zeta potential).
Significant differences are shown as * p < 0.05.
3.1.2. Effect of the Lipid Molar Ratio
Next, we sought how the composition (i.e., lipid molar ratio) affected the particle size, PDI and
surface charge of these LNP formulations (Figures 4–6). The PEG-lipid and structural lipid DSPC
were fixed at 2 and 10 mol% respectively. However, the ratio between cholesterol and the cationic
lipid was varied. The operating microfluidic parameters applied for the assessment of the lipid molar
ratio effect were 3:1 FRR and 20 mL/min TFR (based upon the previous results). Figure 4 shows the
effect of the variation of both cholesterol and cationic lipid molar ratio for the DOTAP formulation.
At low cholesterol content (10 mol%), DOTAP-cLNPs displayed particle sizes of 65 nm and a high PDI
(≥0.4), which further increased after purification (PDI ≥ 0.7) (Figure 4a,b). Increasing cholesterol molar
ratio, and consequently decreasing the ratio of cationic lipid, resulted in a decrease in particle size and
PDI. Particle sizes increased after purification until approximately 50% cholesterol was included into
the formulation, where DOTAP-cLNPs showed comparable particles sizes before and after dialysis
(Figure 4a). Zeta potential values ranged from 0 to +3 mV (Figure 4c).
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Figure 4. Effect of the molar ratio composition on DOTAP-cLNPs, MC3-iLNPs and DDAB-cLNPs.
The molar ratio of DSPC and DMG-PEG2000 was kept constant at 10 and 2 mol% respectively;
however, the ratio of cholesterol and the cationic lipid DDAB was varied from 10–60 and from
78–28 mol% respectively. (a,d,g) Particle size, (b,e,h) PDI and (c,f,i) zeta potential (ZP) of the
DOTAP-cLNPs (pink), MC3-iLNPs (blue) and DDAB-cLNPs (yellow) after microfluidics and after
purification via dialysis (grey). Results represent the mean of at least 3 independent batches and the
standard deviation is plotted as error bars. Significant differences are shown as * p < 0.05 and ‘ns’,
when no statistical significance observed.
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Figure 5. Effect of the structural lipid, the coating lipid and the aqueous buffer choice in the production
of cLNPs based on DOTAP after purification via dialysis. (a) Particle size (bars) and PDI (open circles)
and (b) zeta potential intensities of the cLNPs produced using HSPC (grey) or DSPC (white) as
structural lipid. (c) Particle size (bars) and PDI (open circles) and (d) zeta potential intensities of the
cLNPs produced using DMG-PEG2000 (grey bar) or DSPE-PEG2000 (white bar) LNPs. (e) Particle size
(bars) and PDI (open circles) and (f) zeta potential intensities of the cLNPs produced using TRIS buffer
pH 7.4 10 mM (grey) or citrate buffer pH 6 100 mM as production buffer. Unless otherwise stated,
all the formulations were prepared at 20 mL/min TFR, 3:1 FRR and using citrate buffer as production
buffer (pH 6, 100 mM). Results represent the mean of at least 3 independent batches and the standard
deviation is plotted as error bars. Significant differences are shown as * p < 0.05.
T e effect of the molar ratio of the formulation components on the physicochemical characteristics
of MC3-iLNPs was then evaluated (Figure 4d–f). Unlike DOTAP-cLNPs, varying the cholesterol
content from 10 to 48 mol% (and ther fore reducing MC3 lipid from 78 to 40 m l%), did not affect the
particle size nor the PDI of the particl s produced after microfluidics (Figur 4d,e). These formulatio s
ranged from 45 to 50 nm and showed high homog neous size populations (PDI ≤ 0.2). Only when
60 or 70 mol% cholesterol was chos n, the size of these particles significantly (p < 0.05) increased up
to 70 nm. Opposite to DOTAP-cLNPs, purification of th se particles did not affect the characteristics
at any of the mol% tested (Figure 4d,e). Zeta potential values were neutral for all the formulations
(Figure 4f).
Figure 4g–i shows t e effect of the lipid ratio c ntent on DDAB-cLNPs. In general, increasing the
cholesterol content from 10 to 60 mol% decreased the particle size in a ste dy mann r from 600 nm
down to 56 nm. Particles containi g a low cholesterol molar ratio (10 mol%) were the least stable,
showing large sizes and high PDI values (≈0.6) (Figure 4g,h). However, all other compositions tested
resulted in highly monodispers size distributions, with PDI values below 0.1. DDAB-cLNPs were
purified via dialysis without modifying the physicochemical characteristics (Figure 4g,h). Zeta potential
v lues were neutral for all the formulations (Figure 4i).
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empty DOTAP-cLNPs loading PolyA at N/P 8 and produced at 20 mL/min TFR. Results represent the mean
of at least 3 independent batches and the standard deviation is plotted as error bars. Significant differences
are shown as * p < 0.05.
3.1.3. Effect of the Choice of Structural Lipid, Coating Lipid and Buffer on the Physicochemical
Characteristics of DOTAP-cLNPs
Previously, we have shown the physicochemical characteristics of LNPs produced using
microfluidics with DSPC as a structural lipid and DMG-PEG2000 as the coating lipid. Figure 5a and b
show the effect of replacing DSPC for HSPC on the particle size, PDI and zeta potential of DOTAP-cLNPs
after purification. Microfluidic operating parameters were kept constant at 3:1 FRR and 20 mL/min TFR.
No significant differences were observed among these lipids, with particle sizes of approximately
50 nm, PDI values of 0.2 and neutral zeta potentials for both DSPC and HSPC-containing formulations.
The same results were observed when the PEG-lipid was substituted for a longer hydrocarbon chain
lipid (Figure 5c,d). Replacement of DMG-PEG2000 for DSPE-PEG2000 resulted in DOTAP-cLNPs with
comparable physicochemical characteristics (Figure 5c,d).
Another important parameter during LNP manufacture is the ionic buffer strength and pH. Citrate
buffer at low pH is often used in the preparation of RNA-LNPs containing ionisable/cationic lipids
to decrease base hydrolysis of RNA. However, we sought to examine the effect that TRIS 10 mM pH
7.4 had on the production of DOTAP-cLNP (Figure 5e,f). Additionally, we evaluated the 1:1 and
3:1 FRR. At first glance, we see that cLNPs produced using TRIS buffer are smaller (95 and 25 nm
for 1:1 and 3:1 FRR respectively) compared to cLNPs produced using citrate buffer (180 and 50 nm
for 1:1 and 3:1 FRR respectively) (Figure 5e). Furthermore, DOTAP-cLNPs at 3:1 FRR using TRIS
were significantly (p < 0.05) more heterodisperse (PDI approx. 0.4) compared to those formulated in
citrate buffer. In contrast, the rest of formulations tested showed PDI values below 0.2 (Figure 5e)
regardless of the buffer choice. The effect of the production buffer choice was shown to impact upon the
zeta potential as well. DOTAP-cLNPs produced using TRIS resulted in cationic zeta potential values
between +20 mV and +40 mV, while particles produced using citrate buffer were neutral (Figure 5f).
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Given that the effect of buffer selection during LNP manufacture had a notable impact upon
the final LNP characteristics, we wanted to further explore why TRIS buffer at 3:1 FRR resulted in
a highly heterogeneous particle distribution (Figure 6). Therefore, a stability study was carried out
where these particles were produced using microfluidics (MF, t0h) followed by either: (1) dialysis in
TRIS for 1 h, (2) 5-fold dilution in TRIS (to reduce solvent content down to 5% v/v) or (3) left in 25%
solvent (labelled equilibrium). After each procedure, DLS measurements were performed after 1 h and
4 h. Initially, 20 mL/min TFR was tested (Figure 6a–c). DOTAP-cLNPs showed small particle sizes
(≈25 nm) and high PDI (≈0.4) at t0h. After both dialysis and equilibrium procedures, DOTAP-cLNPs
increased up to 30 and 40 nm after 1 and 4 h respectively (Figure 6a). However, after dilution
in TRIS buffer, the particles remained stable at 30 nm for 4 h, while the PDI decreased down to
0.2 at t4h. Equilibrium also improved the PDI, however the particle size continued to increase over
time (Figure 6b). Figure 6c shows the DLS intensity plots of the same conditions. Next, we decreased
the TFR down to 10 mL/min (Figure 6d–f) where, likewise, the particle size after microfluidics was
approximately 25 nm. However, in this case, the PDI following microfluidics (t0h) was improved
(PDI ≤ 0.25). After dilution and dialysis, DOTAP-cLNPs increased in size up to 30 nm (Figure 6d).
When particles remained in solvent under equilibrium, a significantly (p < 0.05) higher increase (up to
40 nm) was observed. All the particles produced at 10 mL/min showed narrow and unimodal size
distributions, as seen on Figure 6e and f. Finally, these stability conditions were analysed when nucleic
acid (PolyA N/P 8) was encapsulated within the formulation (DOTAP-cLNPs) during manufacture (t0h)
using a TFR of 20 mL/min. The addition of the nucleic acid is shown to act as a stabiliser, where particle
sizes between 40 and 45 nm and monodisperse size distributions were found at all the time points and
across all three conditions tested (dialysis, dilution and equilibrium) (Figure 6g–i).
3.2. Scalability of the Microfluidic Method for Production of iLNPs (GenVoy-ILM™)
The data shown previously was generated using a SHM (Figure 7a). Hence, we have explored
another microfluidic mixer with a TrM as described in a previous publication [14]. For this experiment,
the GenVoy-ILM™ lipid mix composition commercially available from Precision NanoSystems was
selected; this formulation contains an ionisable lipid different from MC3, as the main component.
This ionisable lipid has an apparent pKa of approximately 6.0 (Figure 7b). The pKa is the pH at which
50% of the lipid molecules become positively charged. This can be measured using the TNS assay where
this anionic molecule interacts with cationic particles and emits fluorescence. Blank and PolyA-loaded
GenVoy-ILM™ iLNPs were then produced using the SHM and the TrM at 12, 60 and 200 mL/min TFR
(GMP) (Figure 7c). The blank formulation displayed significantly (p < 0.05) smaller size (≈55 nm size)
compared to its PolyA-loaded counterpart (≈78 nm). Both micromixers showed comparable sizes at all
the speeds tested (Figure 7c), demonstrating the scalability of this microfluidic technology. In addition
to this, high PolyA encapsulation efficiencies (EE ≥ 95%) were achieved (Figure 7d).
3.3. Encapsulation of Nucleic Acids into LNPs
After evaluation of the formulation and microfluidic operating parameters on the physicochemical
characteristics of the empty LNPs, the next step was to determine the impact of the encapsulation
of nucleic acids within these systems. PolyA, ssDNA and mRNA were selected for this study.
Therefore, loaded LNPs were produced at 3:1 FRR and 20 mL/min TFR by adding the nucleic acid in
the aqueous phase (citrate buffer pH 6 100 mM). All three nucleic acids were encapsulated at a fixed
nitrogen to phosphate (N/P) mole ratio of 8. Figure 8 shows the particle size, PDI and zeta potential of
the loaded LNPs before and after purification. PolyA-loaded LNPs showed the same particle sizes
as their empty counterparts (≈47, 52 and 76 nm for DOTAP, MC3 and DDAB-LNPs respectively).
However, when mRNA or ssDNA was encapsulated into these systems, the particle size increased
(Figure 8). Particle sizes remained comparable after purification and the PDI across all formulations
tested was below 0.25 (Figure 8a,b) and high EEs were achieved for all the LNP systems (>95%) (Figure 8).
Cryo-TEM was used for the qualitative analysis of morphological features of the DDAB-cLNPs and
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GenVoy-ILM™ blank and mRNA-loaded formulations (Figure 9). Spherical sub-100 nm particle size
ranges were observed with both DDAB cLNPs and GenVoy-ILM™ iLNPs. We observed that DDAB
cLNPs had a very low electron dense aqueous-filled core containing spherical structure while the
GenVoy-ILM™ iLNPs showing electron dense core containing spherical structure.Pharmaceutics 2020, 12, x FOR PEER REVIEW 12 of 19 
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using citrate buffer (pH 6, 100 mM) at N/P 8 3:1 FRR and 20 mL/min TFR. (a) Particle size and (b) PDI
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of the DSPC:Chol:DOTAP:DMG-PEG2000 (pink), DSPC:Chol:MC3:DMG-PEG2000 (blue) and
DSPC:Chol:DDAB:DMG-PEG2000 (yellow) before and after purification. Encapsulation efficiencies
(EE%) for each formulation are shown as the percentage of the initial amount added (values).
All formulations were prepared at 10:48:40:2 DSPC:Chol:cationic/ionisable:PEG lipid molar ratios.
Results represent the mean of at least 3 independent batches and the standard deviation is plotted as error
bars. Significant differences are shown as * p < 0.05, and ‘ns’, when no statistical significance observed.
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Figure 9. ryo-TE images of blank and mRNA-loaded DDAB-cLNPs (40,000×magnification, 200 kV)
and GenVoy-ILM™ iLNPs (96,000×magnification, 300 kV).
4. Discussions
Since the approval of Onpattro® in 2018 by the Food and Drug Administration, LNPs containing
ionisable lipids have been extensively investigated for the delivery of nucleic acids. Appropriate LNP
designs usually differ depending on the nucleic acid payload and the administration route. For example,
some studies have shown that the optimal pKa value for siRNA-iLNPs is approximately 6.4 [7],
whereas for mRNA-iLNPs it is between 6.6–6.8 [17,18]. In general, optimal parameters consist of
convenient particle size (usually below 100 nm to allow for sterile filtration and effective nucleic
acid delivery), adequate composition, high encapsulation efficiencies (>90%), stability upon storage
and a reproducible and scalable manufacturing method. Microfluidics has previously been shown to
be an effective tool for the manufacture of LNPs [15,16,19,20], liposomes [21–23] and polymer-based
nanoparticles [24–26]. However, the literature lacks reports evaluating the effects of the formulation and
microfluidic operating parameters on the physicochemical characteristics of the LNPs. Within this study,
we evaluated the effect of the total flow rate (TFR) and flow rate ratio (FRR), as well as the impact of
the choice of structural lipid, PEG-lipid and aqueous buffer on the particle size, PDI and zeta potential
of LNPs. Moreover, we encapsulated three types of nucleic acids within LNPs to assess their effect on the
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LNP physicochemical characteristics and on the encapsulation efficiency. Since microfluidics is based
on the mixing of two liquid streams (lipids dissolved in organic solvent are mixed with an aqueous
phase containing a nucleic acid at specific FRR and at selected TFR), we initially evaluated the effect of
these operating parameters on three LNP systems consisting on DSPC, cholesterol, cationic (DOTAP or
DDAB) or ionisable lipid (MC3) and DMG-PEG2000 at 10:48:40:2 molar ratio respectively. Lou et al. [13]
produced a panel of cationic LNPs encapsulating a self-amplifying mRNA (N/P 8) using the same
microfluidic technology used in this study. These cLNPs were compared to previously described
MC3-based iLNPs [15]. All these LNPs were produced in methanol at 10:48:40:2 molar ratio at 3:1 FRR
and 5 mL/min TFR. From this study, cLNPs based on DDAB and DOTAP showed the highest potency
in vitro and induced comparable antibody responses to the benchmark iLNPs. Therefore, due to
their good efficacy in vivo and the commercial availability to purchase these cationic/ionisable lipids,
we selected these three LNPs (DDAB, DOTAP and MC3-based) for our microfluidic manufacture
optimisation. We first optimized the production speed, which is an important parameter to consider,
as this could restrict the manufacturing time. The majority of the literature reports no impact of this
parameter on the manufacture of lipid-based delivery systems [14,22,27]. However, we have previously
reported a reduction in the particle size of cationic liposomes based on DDAB:TDB when increasing the
flow rate from 5 to 15 mL/min [21]. Here, we have shown that, at low TFR, the particles are significantly
(p < 0.05) larger (Figure 2). Therefore, we hypothesize that the reduced mixing within the microfluidic
micromixer at 5 mL/min results in a slow dilution of the solvent, promoting the formation of larger
particles. On the other hand, the effect of the FRR on vesicle physicochemical characteristics has been
extensively reported [14,22,23,28]. In general, increasing the FRR, and therefore, increasing polarity,
creates a narrow organic solvent stream, which aids the formations of smaller particles due to reduced
particle fusion [11]. In addition to this, here we observed destabilisation and stabilisation of LNPs
when formulated at 1:1 FRR (Figure 3). It has been reported in the literature that the production of
LNPs at 1:1 FRR using a T-shape mixer gave rise to metastable particles which required further dilution
to be stabilised [29]. This could explain the results observed in Figure 3. DOTAP-cLNPs stabilised
after the removal of solvent via dialysis; however, MC3-iLNPs became more unstable after dialysis.
These results suggest that MC3 is more sensitive to organic solvent, and a faster removal or decrease of
solvent content within the formulation (e.g., dilution) may improve the physicochemical characteristics
of these iLNPs.
Next, we evaluated the effect of the individual lipid content on the size, PDI and zeta potential of
the cLNP and iLNP systems (Figure 4). The aim of this experiment was to assess if minimal and large
modifications on the molar lipid content could be detected by the physicochemical characteristics of
the formed particles. Process analytical techniques such as AT-line sizers could be implemented in
the manufacture process and therefore, this would allow for the quick detection of deviations in LNP
composition if large production of LNPs is required [23]. LNPs generally require four components:
a phospholipid, cholesterol, a permanent cationic or ionisable lipid and a PEG-lipid. Each of these
components has a specific role within the formulation. There is limited information about the role
of phospholipids (commonly DSPC) and cholesterol in the activity of LNPs [30]. However, it has
been reported that both DSPC and cholesterol, promote stability, contributing to the structural
integrity of the formulation [31]. In addition to this, DSPC increases membrane rigidity and decreases
membrane permeability due to its high transition temperature (55 ◦C). Some studies have reported that
cholesterol-free or cholesterol-deficient LNPs might have possible destabilisation effects which might
result in decreased LNP potency [32,33]. These lipids aid in the encapsulation of the nucleic acids.
PEG-lipid plays several roles. It is located on the surface of the LNPs and it dictates the particle size
of the LNPs during manufacture [16]. Production of LNPs in acidic pH without PEG-lipid would
promote particle fusion [9]. In addition to this, they increase product shelf-life and in vivo circulation
lifetime [34]. Finally, the role of the ionisable or cationic lipid is to both promote electrostatic interaction
with the negatively charged nucleic acids and promote intracellular delivery. Moreover, ionisable lipids
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facilitate endosomal escape through fusion with the endosome membrane as a result of the cationic
charge under endosomal pH [35].
We further explored the effect of replacing the phospholipid or the PEG-lipid into the particle size
of the LNPs. No impact on the physicochemical characteristics of the DOTAP-cLNPs was observed
(Figure 5). It has been reported elsewhere that the type of phospholipid selected for formulation within
the LNPs influences the LNP potency [18]. Regarding the choice of PEG-lipid, short hydrocarbon
chains (C14 -DMG-PEG2000) that diffuse out of the LNPs enhance intracellular delivery [34,36,37].
However, C18 chains (DSPE-PEG2000), do not dissociate as easily, contributing to an extended
circulation lifetime [38]. As well as lipid content, another important parameter to consider is the aqueous
buffer. Citrate buffer at a low pH is commonly used for the production of RNA LNPs since it reduces the
hydrolysis of RNA due to the chelating effect of sodium citrate. However, for experimental purposes,
we sought to study the effect that the well-known TRIS buffer (commonly prepared at physiological,
pH 7.4) had on the LNP production by microfluidics. The non-ionisable DOTAP-cLNPs were selected
for this purpose. TRIS demonstrated an impact on the zeta potential of the cLNPs, displaying positive
zeta potentials compared to the neutral charge observed on cLNPs produced using citrate buffer. It is
hypothesised that the reactive amine group within the TRIS structure becomes protonated, resulting in
cationic zeta potentials. Moreover, the effect that buffer type and concentration have on liposomal
systems produced using microfluidics has been previously explained by Lou et al. [39]. Lou et al.
demonstrated that DSPC:Chol:DOTAP liposomes were larger (approx. 100 nm) when prepared using
citrate buffer pH 6 compared to TRIS buffer pH 7.4 (approx. 60 nm) even at the same buffer molarity [39].
Particle size was dependent on buffer type, concentration and cationic lipid content. The higher the
cationic lipid content or the buffer concentration, the larger the particle size [38]. It was hypothesised
that the presence of electrolytes may decrease lipid head repulsion, affecting the packing of the lipids
and thus producing large cationic liposomes. Furthermore, we observed that using TRIS buffer for
the preparation of DOTAP-based LNPs at high flow rates (20 mL/min) produced small and unstable
LNPs (Figure 6). We hypothesise that a combination of both high production speeds and buffer
choice contribute to the formation of very small particles that need more time to form, and thus, after
equilibrium or dilution, these particles reach their stability. However, we have also demonstrated that
particle stability can be achieved by reducing the flow rate (TFR) or by encapsulating nucleic acids
(Figure 6). The encapsulation of PolyA contributed to the stabilisation of the particles by means of the
electrostatic interactions between the positively charged LNPs and the negatively charged nucleic acid.
Encapsulation of a nucleic acids with different molecular weights resulted in particle sizes below
100 nm (Figure 8), which have been reported in the literature to be more potent than larger particle sizes,
with optimum LNP potency displayed at approximately 80 nm [37,40]. Moreover, there was a consistent
range of particle sizes, as indicated by DLS and Cryo-TEM. Lou et al. produced self-amplifying
mRNA-LNPs with the same lipid composition as the ones tested in this study, with particle sizes
between 80–100 nm, a narrow size distribution and high encapsulation efficiencies (>95%) [13].
Blakney et al. also prepared self-amplifying mRNA-loaded LNPs based on the cationic lipids DOTAP
and DDAB or on the ionisable lipid C12–200 [41]. These LNPs were prepared using a microfluidic
platform different from the one presented here, and no significant differences were observed on
their physicochemical characteristics (100–200 nm, PDI ~0.2) [41]. Morphological characterisation of
blank and mRNA-loaded DDAB-cLNPs and GenVoy-ILM™-iLNPs (Figure 9) showed comparable
morphology to what it has previously been reported in literature and particle sizes were in agreement
with the DLS measurements (e.g., [13,42]). Blank and mRNA-loaded iLNPs revealed an electron
dense core, suggesting that the ionisable lipid contributes to this appearance when not complexed to
nucleic acids [43]. On the other hand, blank DDAB-cLNPs showed a less dense interior [13].
The use of SHM allows for rapid and reproducible manufacture at bench to clinic scale.
GMP production using a SHM would result in an expensive task, due to the need of parallelization of
the micromixers. However, the use of a TrM represents an advantage since it allows higher throughputs,
favouring the progression from bench (mL) to GMP-scale (L) [14,44]. We have previously demonstrated
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the ability of the TrM to produce protein-loaded liposomes on a large scale (L) and high speeds
(200 mL/min) [14]. Here, we have demonstrated the scalability of microfluidics for the manufacture of
nucleic acid-loaded iLNPs at high production speeds required for large-scale GMP-manufacturing
conditions (Figure 7). This is a hot topic nowadays, since due to the SARS-CoV-19 pandemic, there is a
high demand for scalable techniques for mass vaccination, and there are currently a number of vaccines
in clinical trials based on RNA-LNP systems.
5. Conclusions
Here, we have shown a comprehensive study of the effect of the formulation components and
the microfluidic process parameters on the physicochemical characteristics of LNPs. The cationic
(DDAB and DOTAP) and ionisable (MC3) LNPs tested have shown high sensitivity to the microfluidic
operating parameter flow rate ratio and the total flow rate. Swapping structural lipids or PEG-lipids
resulted in similar trends being interchangeable. Buffer choice and molar lipid content are important
considerations for LNP manufacture, as these influenced LNP size and stability. In addition to this,
microfluidics allows for a wide range of nucleic acids (e.g., PolyA, ssDNA, mRNA) to be accommodated.
This method of optimisation and formulation screening could be used as a guide for the preparation of
LNPs for gene delivery.
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